PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8595642-6	1995	Lovastatin significantly decreased levels of total cholesterol, calculated LDL, directly measured LDL, IDL, total triglycerides, VLDL, and the ratios of LDL:HDL, total cholesterol:HDL, and directly measured LDL:HDL and significantly increased total HDL and HDL3 levels.	Lovastatin	0-10	HDL3	Homo sapiens	257-261	
8595642-7	1995	Gemfibrozil was significantly more effective than lovastatin in raising total HDL and HDL3 levels and in lowering the IDL plus VLDL:HDL ratio.	Lovastatin	50-60	HDL3	Homo sapiens	86-90	
1613316-3	1992	Gemfibrozil and lovastatin caused primarily similar alterations in HDL components in HDL2 and HDL3 subfractions.	Lovastatin	16-26	HDL3	Homo sapiens	94-98	
8434806-2	1993	Lovastatin therapy caused greater percentage changes in HDL2 than in HDL3.	Lovastatin	0-10	HDL3	Homo sapiens	69-73	
1613316-6	1992	Gemfibrozil increased the cholesterol concentrations of HDL2 and HDL3 (p less than 0.05 for both), and lovastatin caused significant increases in HDL2 (p less than 0.05) and HDL3 phospholipids (p less than 0.01).	Lovastatin	103-113	HDL3	Homo sapiens	174-178	
2079605-3	1990	Lovastatin caused reduction of the apparent number of 125I-labeled HDL3 binding sites without affecting the binding affinity.	Lovastatin	0-10	HDL3	Homo sapiens	67-71	
2079605-5	1990	Mevalonic acid reversed the effect of lovastatin on 125I-labeled HDL3 binding.	Lovastatin	38-48	HDL3	Homo sapiens	65-69	
2079605-6	1990	Lovastatin blocked up-regulation of the HDL receptor in response to loading of cells with nonlipoprotein cholesterol and modified cholesterol-induced changes of 125I-labeled HDL3 degradation.	Lovastatin	0-10	HDL3	Homo sapiens	174-178